Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.42
PAH's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 0.42 )
PAH' s 10-Year Cash to Debt Range
Min: 0.42   Max: No Debt
Current: 0.42

Equity to Asset 0.50
PAH's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 0.50 )
PAH' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.5
Current: 0.5

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 15.74
PAH's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 15.74 )
PAH' s 10-Year Operating margin (%) Range
Min: 7.68   Max: 15.74
Current: 15.74

7.68
15.74
Net-margin (%) 6.29
PAH's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 6.29 )
PAH' s 10-Year Net-margin (%) Range
Min: 0.14   Max: 6.29
Current: 6.29

0.14
6.29
ROE (%) 16.86
PAH's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 16.86 )
PAH' s 10-Year ROE (%) Range
Min: 16.86   Max: 16.86
Current: 16.86

ROA (%) 3.73
PAH's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 3.73 )
PAH' s 10-Year ROA (%) Range
Min: 3.73   Max: 3.73
Current: 3.73

ROC (Joel Greenblatt) (%) 49.99
PAH's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 49.99 )
PAH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 49.99   Max: 49.99
Current: 49.99

» PAH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

PAH Guru Trades in

PAH Guru Trades in

PAH Guru Trades in

Q1 2014

PAH Guru Trades in Q1 2014

Ron Baron 3,333,333 sh (New)
Louis Moore Bacon 250,000 sh (New)
Murray Stahl 3,553,037 sh (New)
John Griffin 8,000,000 sh (New)
Whitney Tilson 227,400 sh (New)
Bill Ackman 33,333,330 sh (New)
Leon Cooperman 266,666 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PAH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Griffin 2014-03-31 New Buy1.7%$13.5 - $21.82 $ 24.640%8000000
Ron Baron 2014-03-31 New Buy0.26%$13.5 - $21.82 $ 24.640%3333333
Leon Cooperman 2014-03-31 New Buy0.07%$13.5 - $21.82 $ 24.640%266666
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Platform Specialty Products Corp

Murray Stahl’s Horizon Kinetics Comments on Platform Specialty Products - Jun 26, 2014

A recent purchase in certain strategies is Platform Specialty Products (PAH). Like Wendy’s (WEN), this stock does not trade at a presently low price-to-earnings, or P/E ratio; in fact, it’s somewhat high. However, the company incorporates many predictive attributes that are suggestive that its revenues and earnings several years from now will be far higher than they are today. As a U.S. company, PAH is new, having been listed on the NYSE only since this past January. Its operating business, though, has been around for over 90 years, and PAH was trading on the London Stock Exchange when it was acquired this past October for $1.8 billion by what is known as a blank-check company. The current stock market value is $2.4 billion. A blank check company raises equity capital in order to acquire a target, often within a specified window of time, and this particular one was organized by three well- known parties: Nicolas Beggruen, through his investment company Beggruen Holdings; Bill Ackman, through his hedge fund Pershing Square; and Martin Franklin. At year-end they each controlled, respectively, 6.5 million, 33.3 million, and 7.3 million shares. Martin Franklin is also the founder and Executive Chairman of Jarden Corp (JAH), which is a significant holding in the Core Value and Strategic Value strategies, among others. The same three, also through a blank check company, brought Burger King (BKW) public again in mid-2012.



PAH produces specialty chemicals for a wide range of industries. It manufactures over 1,000 compounds, and its largest customer represents only 3% of sales. It exhibits very little cyclicality. Energy costs are only 2% of sales. It’s important to qualitatively differentiate the nature of the PAH chemicals business from that of the typical chemicals company. These particular chemicals are often proprietary both as to makeup (the company has over 750 patents) and process. Their employees spend considerable time with customers guiding them as to how to use these chemicals, often in multi-step processes, such as might be used to enhance the performance of a circuit board. PAH refers to these as dynamic chemistries and seeks out markets requiring highly technical post-sale customer service. What PAH sells tend to represent a very small portion of the cost of a customer’s product, yet are important to the product’s function or appearance. According to the company, customer retention is very high because the cost savings from switching to another provider are modest, while the switching costs are high due to process complexities and quality control requirements.



All of these attributes differentiate PAH from commodity chemical providers. Perhaps the most obvious way to observe this is via the balance sheet: whereas total assets are $2.2 billion, property, plant and equipment are only $140 million. Now, the balance sheet is distorted because of $1.7 billion of goodwill and intangible assets; nevertheless, $140 million of production assets is inordinately small relative to $750 million of annual revenue and $383 million of current assets. Accordingly, PAH has more of the character of a branded products business than of a commodity business. If so, it should have greater than average pricing power and modest capital expenditure requirements, which should also be reflected in the financial statements, which they are: capital expenditures are only about $10 million per year, such that free cash flow is about equal to net income, and the 2013 free cash flow margin was about 11.8%. As a point of comparison, to pick a branded consumer products company, General Mills (GIS) had a 9.4% net profit margin last year.



The reason the proprietary-product character of PAH is intriguing is because it bears certain commonalities with Jarden Corp., which is a branded products company. Jarden, which we’ve reviewed in the past, has been a very skilled acquirer and integrator of branded products, its portfolio comprised exclusively of either the leading market share products in their categories or the second largest market share. These range from Bee and Bicycle playing cards to Bionaire, Mr. Coffee, Oster and Sunbeam home and kitchen appliances, to Aerobed mattresses, Coleman camping gear, and on and on. Mr. Franklin’s curricula vitae at Jarden include these two statistics: book value per share, from 2001, when he assumed control, through 2013, expanded at a 26.4% annual rate; earnings per share have increased at a 20.2% rate.



The relevance of the relationship of Jarden and Mr. Franklin to the PAH investment thesis is this: it was a stated goal of the blank check company to identify a suitable target not merely to acquire it but also to use it as a platform for additional acquisitions in its industry. PAH, as a company that has relatively proprietary products and which generates relatively high free cash flow, can afford to fund additional acquisitions. Many large companies in recent years, in order to demonstrate a single-minded focus on their core business lines and maximize their returns on capital, have been spinning off or otherwise divesting lesser or ancillary divisions. The chemicals industries are no exception. The buyers have been entrepreneurs and private equity firms. A sterling example of just such a strategy well executed, aside from Jarden, is Colfax Corp. (CFX), established by the Rales brothers, and which came public in 2008. It is also a holding in Core Value and Strategic Value. Not a quarter goes by without one or more acquisitions, in their case, of generally modest-size industrial companies that manufacture gas- and fluid-handling products and services. If you simply look at the 5-or 6-year price chart, you get the picture.



In this instance, the qualitative assessment is of particular importance. The thesis is that Mr. Franklin will oversee a series of acquisitions, priced well, integrated effectively, eventually with the further benefit of scale economies, and that there will be a suitably large supply of acquisition candidates. If this thesis bears fruit, one can readily see that in success mode PAH can be far, far larger in the foreseeable, though not near, future. The rewards for the patient would be suitable.



From Murray Stahl‘s First Quarter 2014 Market Commentary.



Check out Murray Stahl latest stock trades

Top Ranked Articles about Platform Specialty Products Corp

Murray Stahl’s Horizon Kinetics Comments on Platform Specialty Products
A recent purchase in certain strategies is Platform Specialty Products (PAH). Like Wendy’s (WEN), this stock does not trade at a presently low price-to-earnings, or P/E ratio; in fact, it’s somewhat high. However, the company incorporates many predictive attributes that are suggestive that its revenues and earnings several years from now will be far higher than they are today. As a U.S. company, PAH is new, having been listed on the NYSE only since this past January. Its operating business, though, has been around for over 90 years, and PAH was trading on the London Stock Exchange when it was acquired this past October for $1.8 billion by what is known as a blank-check company. The current stock market value is $2.4 billion. A blank check company raises equity capital in order to acquire a target, often within a specified window of time, and this particular one was organized by three well- known parties: Nicolas Beggruen, through his investment company Beggruen Holdings; Bill Ackman, through his hedge fund Pershing Read more...
Bill Ackman Announces 30.9% Stake in Platform Specialty Products
On Jan. 23, Pershing Square founder Bill Ackman (Trades, Portfolio) disclosed ownership of 33,333,332 shares, or 30.9% ownership, of Platform Specialty Products (PAH). The 13G filing came on the same day the company began trading on the New York Stock Exchange and requested to cancel its former listing on the London Stock Exchange. His holding consists of 29,166,665 common shares and 12,500,001 warrants to purchase an additional 4,166,667 common shares, and makes him the company’s largest institutional shareholder. Read more...

Ratios

vs
industry
vs
history
P/B 1.00
PAH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 1.00 )
PAH' s 10-Year P/B Range
Min: 0   Max: 2.7
Current: 1

0
2.7
P/S 4.10
PAH's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 4.10 )
PAH' s 10-Year P/S Range
Min: 0   Max: 4.8
Current: 4.1

0
4.8
EV-to-EBIT 22.20
PAH's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 22.20 )
PAH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 22.2

Current Ratio 5.22
PAH's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 5.22 )
PAH' s 10-Year Current Ratio Range
Min: 5.22   Max: 5.22
Current: 5.22

Quick Ratio 4.47
PAH's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PAH: 4.47 )
PAH' s 10-Year Quick Ratio Range
Min: 4.47   Max: 4.47
Current: 4.47

Valuation & Return

vs
industry
vs
history

Business Description

Industry: »
Compare: » details
Traded in other countries:PAH.UK
Platform Acquisition Holdings PLC is a cash shell company looking to undertake an acquisition of a target company or business that is expected to have an enterprise value of between $750 million and $2.5 billion, though a target company or business with a smaller or larger enterprise value may be considered.
» More Articles for PAH

Headlines

Articles On GuruFocus.com
Murray Stahl’s Horizon Kinetics Comments on Platform Specialty Products Jun 26 2014 
Activist Bill Ackman's First Quarter Top Positions May 16 2014 
Kase Capital's Whitney Tilson Reports 3 New Stock Buys May 07 2014 
Kase Capital's Whitney Tilson Reports 3 New Stocks May 07 2014 
GuruFocus Real Time Picks of the Week Jan 31 2014 
Bill Ackman Announces 30.9% Stake in Platform Specialty Products Jan 27 2014 

More From Our Partners
3 Stocks Pushing The Technology Sector Lower Jul 23 2014 - THESTREET

More From Other Websites
Platform Specialty Products Corporation Announces Date for Release of Second Quarter 2014 Financial... Jul 23 2014
MacDermid Inc. -- Moody's affirms Platform's B1 CFR, assigns B1 to AgroSolutions acquisition... Jul 22 2014
PLATFORM SPECIALTY PRODUCTS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 21 2014
PLATFORM SPECIALTY PRODUCTS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 11 2014
A Long-Term Approach: Christopher Tsai On Investing In Asia Jun 26 2014
Is This The Next Blockbuster Deal For Bill Ackman? Jun 16 2014
PLATFORM SPECIALTY PRODUCTS CORP Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 13 2014
[video] Charge Into Visa, Platform Specialty and Colfax Corporation Jun 10 2014
PLATFORM SPECIALTY PRODUCTS CORP Financials May 24 2014
Platform Specialty Products files to sell 14.825M shares of common for holders May 23 2014
PLATFORM SPECIALTY PRODUCTS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 21 2014
Platform Specialty Products Corporation Announces Closing of $300.2 Million Private Placement of... May 21 2014
Why Ackman exited Procter and Gamble stake? May 21 2014
Why Pershing exited General Growth Properties in 1Q14 May 21 2014
Why Ackman teamed up with Valeant to bid for Allergan May 20 2014
Why Ackman started position in Home Properties May 20 2014
Why Pershing opened new position in AIMCO May 20 2014
Must-know: Bill Ackman’s Pershing Square 1Q14 positions May 19 2014
Pershing Square gives quarterly update on stakes May 15 2014
Ackman dumps remainder of P&G stake May 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide